A lysosomal enigma CLN5 and its significance in understanding neuronal ceroid lipofuscinosis

Basak, Indranil; Wicky, Hollie E; McDonald, Kirstin O; Xu, Janet Boyu; Palmer, Janet. E; Best, Hannah L; Lefrancois, Stephane ORCID: https://orcid.org/0000-0002-3312-9594; Lee, Sang Yoon; Schoderboeck, Lucia et Hughes, Stephanie M (2021). A lysosomal enigma CLN5 and its significance in understanding neuronal ceroid lipofuscinosis Cellular and Molecular Life Sciences , vol. 78 , nº 10. pp. 4735-4763. DOI: 10.1007/s00018-021-03813-x.

Prévisualisation	PDF - Version publiée Disponible sous licence Creative Commons Attribution. Télécharger (3MB) | Prévisualisation
Prévisualisation	PDF - Version mise à jour Disponible sous licence Creative Commons Attribution Non-commercial. Télécharger (505kB) | Prévisualisation

Résumé

Neuronal Ceroid Lipofuscinosis (NCL), also known as Batten disease, is an incurable childhood brain disease. The thirteen forms of NCL are caused by mutations in thirteen CLN genes. Mutations in one CLN gene, CLN5, cause variant late-infantile NCL, with an age of onset between 4 and 7 years. The CLN5 protein is ubiquitously expressed in the majority of tissues studied and in the brain, CLN5 shows both neuronal and glial cell expression. Mutations in CLN5 are associated with the accumulation of autofluorescent storage material in lysosomes, the recycling units of the cell, in the brain and peripheral tissues. CLN5 resides in the lysosome and its function is still elusive. Initial studies suggested CLN5 was a transmembrane protein, which was later revealed to be processed into a soluble form. Multiple glycosylation sites have been reported, which may dictate its localisation and function. CLN5 interacts with several CLN proteins, and other lysosomal proteins, making it an important candidate to understand lysosomal biology. The existing knowledge on CLN5 biology stems from studies using several model organisms, including mice, sheep, cattle, dogs, social amoeba and cell cultures. Each model organism has its advantages and limitations, making it crucial to adopt a combinatorial approach, using both human cells and model organisms, to understand CLN5 pathologies and design drug therapies. In this comprehensive review, we have summarised and critiqued existing literature on CLN5 and have discussed the missing pieces of the puzzle that need to be addressed to develop an efficient therapy for CLN5 Batten disease.

Type de document:	Article
Mots-clés libres:	Batten Disease, Neuronal Ceroid Lipofuscinosis, Lysosome, CLN5, Neurodegeneration
Centre:	Centre INRS-Institut Armand Frappier
Date de dépôt:	22 juin 2022 19:11
Dernière modification:	27 févr. 2024 19:45
URI:	https://espace.inrs.ca/id/eprint/12290

Gestion Actions (Identification requise)

Modifier la notice